OptimizeRx (NASDAQ:OPRX) Stock, Quote.Headers.trade-ideas

OptimizeRx

OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.

Gold.goldbar.goldnugget.shutterstock

Earnings

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AEMD

ARCO

EDBL

OPRX

PXLW

VRPX

Gold Rises Over 1%; Arcos Dorados Shares Fall After Q1 Results

movers

Movers

ARQT

AWIN

BCRX

BOLT

BSFC

CABA

CDRO

CRKN

CSLR

CTNT

DELL

DLPN

FFIE

GWAV

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

INTZ

IRBT

JFBR

KOSS

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MNDY

NOVA

NSYS

NTRB

NVAX

PEGY

PLSE

RIVN

RSKD

SINT

SLNA

SPCE

SPWR

VTSI

YTEN

Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Wall street shutter3

Nasdaq Surges 150 Points; Retail Sales Flat For April

OptimizeRx Corp

The company announced an expansion of a strategic relationship with a major pharma client via a muti-solution, multi-brand program bringing the total in year commitment to over&nbsp;$10 million, which includes the previously mentioned&nbsp;$6 million&nbsp;DAAP contract.

OptimizeRx Reports Expansion Of Strategic Relationship With A Major Pharma Client

The availability of Micro-Neighborhood&#xAE; Targeting on the Company's Dynamic Audience Activation Platform meets the demand of life sciences marketers by synchronizing consumer and physician marketing &nbsp;
OptimizeRx presents panel session at Digital Pharma East: <a href="https://www.globenewswire.com/Tracker?data=tA8fr7L7-ld-_-9wCncWqKYet1Ol7b6SNxjLAGWIcKvwcp0dLLrBdptpiHgJWlAe_Q8GZOtO39Npqs6U7Ds-42asCziNzXfO-fs__vLwBCPody91dY1lKEo0nuzrEYllnUOzd1U4eOX2VPLo_2k0x85YUYFIZL6K6KY_EcwYW8uxn9pssdkhQUJTkltn7Zcajj3kri_UL8tlyaAH_B6WmVYt1KUPK5402HscogcxTkI=">Unlocking Opportunity through HCP+DTC Alignment in Omnichannel Oncology Marketing</a>
WALTHAM, Ma., Sept. 09, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Jfzc90X4JJ4E98QXu1l9MKC1luzvAnAn2OESeY69lDmOv_BThNL8Qdt2ESFlnsGAJYfjkxiZ7dC7IHWEGa52cdX-KVrbftwIDbKI5UCR-J8=">OptimizeRx Corp</a>. (the "Company")&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and prospective patients, today announces the leading AI-driven marketing technology for healthcare consumers, Micro-Neighborhood Targeting (MNT), offered on the Company's Dynamic Audience Activation Platform (DAAP), which now further unifies outreach to patient and provider audiences via the incorporation of brand eligibility signals to consumer marketing. This enhancement to DAAP enables pharmaceutical brands to deliver synchronized, AI-guided Direct-to-Consumer (DTC) and HCP campaigns, with the mission to improve the dialogue between patients and physicians throughout the treatment journey.

OptimizeRx Launches Micro-Neighborhood Targeting, Offered On The Co's Dynamic Audience Activation Platform, Further Unifing Outreach To Patient And Provider Audiences Via The Incorporation Of Brand Eligibility Signals To Consumer Marketing

RBC Capital analyst Sean Dodge maintains OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Outperform and lowers the price target from $17 to $14.

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on OptimizeRx, Lowers Price Target to $14

In the latest quarter, 5 analysts provided ratings for OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>), showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated OptimizeRx and provided 12-month price targets. The average target is $14.4, accompanied by a high estimate of $16.00 and a low estimate of $11.00. A decline of 4.0% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1723471210_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of OptimizeRx's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$11.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>David Grossman</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to OptimizeRx. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of OptimizeRx compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of OptimizeRx's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of OptimizeRx's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OPRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on OptimizeRx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind OptimizeRx</h2>
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
<h3>Unraveling the Financial Story of OptimizeRx</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining OptimizeRx's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 51.43% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: OptimizeRx's net margin excels beyond industry benchmarks, reaching -35.04%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): OptimizeRx's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -5.54%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -3.84%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.3, OptimizeRx adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Closer Look at 5 Analyst Recommendations For OptimizeRx

Barclays analyst Stephanie Davis maintains OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Equal-Weight and lowers the price target from $15 to $11.

Barclays Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $11

Guidance

OptimizeRx Reiterates 2024 Guidance And Expects Revenue To Be At Least $100M (Est $101.458M) With Adjusted EBITDA Of At Least $11M

OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.06) by 133.33 percent. This is a 300 percent increase over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $18.812 million which missed the analyst consensus estimate of $20.195 million by 6.85 percent. This is a 36.14 percent increase over sales of $13.818 million the same period last year.

Earnings Beats

Earnings Misses

OptimizeRx Q2 2024 Adj. EPS $0.02 Beats $(0.06) Estimate, Sales $18.812M Miss $20.195M Estimate

JMP Securities analyst Constantine Davides reiterates OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Market Outperform and maintains $16 price target.

Reiteration

JMP Securities Reiterates Market Outperform on OptimizeRx, Maintains $16 Price Target

7 analysts have shared their evaluations of OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $15.0, a high estimate of $17.00, and a low estimate of $13.00. Surpassing the previous average price target of $14.25, the current average has increased by 5.26%.
<img src="https://www.benzinga.com/files/images/story/2024/1718985674_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive OptimizeRx. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>David Grossman</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>David Grossman</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$17.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to OptimizeRx. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of OptimizeRx compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of OptimizeRx's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of OptimizeRx's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/OPRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on OptimizeRx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into OptimizeRx's Background</h2>
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
<h3>OptimizeRx: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, OptimizeRx showcased positive performance, achieving a revenue growth rate of 51.43% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: OptimizeRx's net margin is impressive, surpassing industry averages. With a net margin of -35.04%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): OptimizeRx's ROE stands out, surpassing industry averages. With an impressive ROE of -5.54%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): OptimizeRx's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -3.84%, the company may face hurdles in achieving optimal financial returns.
Debt Management: OptimizeRx's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.3.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Critical Insights From OptimizeRx Analyst Ratings: What You Need To Know

U.S. stocks traded higher toward the end of trading, with the S&amp;P 500 gaining around 1% on Wednesday.
The Dow traded up 0.68% to 39,827.63 while the NASDAQ rose 1.29% to 16,723.91. The S&amp;P 500 also rose, gaining, 1.03% to 5,300.57.
Check This Out: <a href="https://www.benzinga.com/news/24/05/38840839/wall-streets-most-accurate-analysts-views-on-3-materials-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts&#8217; Views On 3 Materials Stocks Delivering High-Dividend Yields</a>
Leading and Lagging Sectors Utilities shares rose by 1.5% on Wednesday.
In trading on Wednesday, energy shares fell by 0.8%.
Top Headline
Shares of Arcos Dorados Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARCO#NYSE">ARCO</a>) fell around 5% on Wednesday after reporting results for its first quarter
The company reported total revenues of $1.081 billion in the first quarter, up 9.1% versus the prior year. Quarterly sales marginally beat the analyst consensus of $1.020 billion. Arcos Dorados reported first-quarter earnings per share of 14 cents, missing the street view of 17 cents.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>OptimizeRx Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) shares shot up 23% to $12.90 following upbeat quarterly results.</li>
<li>Shares of Edible Garden AG Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>) got a boost, surging 30% to $5.57 following first-quarter results.</li>
<li>iPower Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPW#NASDAQ">IPW</a>) shares were also up, gaining 34% to $1.19 after the company reported better-than-expected third-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares dropped 66% to $0.7796 after the company reported pricing of $2.25m public offering.</li>
<li>Shares of Pixelworks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXLW#NASDAQ">PXLW</a>) were down 35% to $1.22 after the company issued soft second-quarter guidance.</li>
<li>Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) was down, falling 47% to $0.4542 after the company announced pricing of $4.7 million public offering.</li>
</ul>
Also Check This Out:<a href="https://www.benzinga.com/24/05/38840642/dell-to-rally-over-13-here-are-10-top-analyst-forecasts-for-wednesday">Dell To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Wednesday</a>
Commodities In commodity news, oil traded up 0.8% to $78.63 while gold traded up 1.5% at $2,392.90.
Silver traded up 3.7% to $29.755 on Wednesday, while copper rose 0.7% to $4.9290.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.59%, Germany's DAX rose 0.82% and France's CAC 40 rose 0.17%. Spain's IBEX 35 Index rose 1.10%, while London's FTSE 100 rose 0.21%.
Industrial production in the Eurozone increased by 0.6% month-over-month in March compared to a revised 1% gain in the previous month. The Eurozone economy grew by 0.3% on quarter during the first three months, compared to a 0.1% decline in the prior quarter.
The annual inflation rate in France fell to 2.2% in April from 2.3% in March.
Asia Pacific Markets
Asian markets closed mostly lower on Wednesday, with Japan's Nikkei gaining 0.08%, China's Composite Index falling 0.82%, Hong Kong's Hang Seng Index falling 0.22% and India's S&amp;P BSE Sensex falling 0.22%.
Total passenger vehicle sales in India rose 1.2% year-over-year to 287,746 in April compared to an 8.9% rise in the prior month. The People&#8217;s Bank of China kept the interest rate unchanged at 2.50%.
Economics
<ul>
<li>Mortgage applications in the US rose 0.5% from the prior week in the period ending May 10.</li>
<li>U.S. consumer prices rose 0.3% month-over-month in April compared to 0.4% in the previous month, and also down from market expectations of 0.4%.</li>
<li>Annual inflation rate in the U.S. slowed to 3.4% in April from 3.5% a month ago.</li>
<li>U.S. retail sales came in unchanged month-over-month in April compared to a revised 0.6% increase in March.</li>
<li>The NY Empire State Manufacturing Index declined to -15.6 in May compared to -14.3 in the prior month, and versus market estimates of -10.0.</li>
<li>Total business inventories declined by 0.1% month-over-month in March compared to a revised 0.3% gain in February.</li>
<li>The NAHB/Wells Fargo Housing Market Index declined to 45.0 in May, recording the lowest level in four months.</li>
<li>Crude oil inventories in the U.S. declined by 2.508 million barrels in the week ending May 10, compared to a 1.362 million gain in the prior period.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/05/38839679/top-3-consumer-stocks-that-could-blast-off-this-month&quot;">Top 3 Consumer Stocks That Could Blast Off This Month</a>

JMP Securities analyst Constantine Davides maintains OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Market Outperform and raises the price target from $15 to $16.

JMP Securities Maintains Market Outperform on OptimizeRx, Raises Price Target to $16

Shares of Bolt Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) fell sharply during Wednesday's session after the company reported <a href="https://www.benzinga.com/quote/BOLT/earnings">first-quarter financial results</a>.
Bolt Biotherapeutics posted a GAAP loss of 28 cents per share on sales of $5.30 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Also, Guggenheim analyst Michael Schmidt downgraded Bolt Biotherapeutics from Buy to Neutral, while Stifel analyst Stephen Willey downgraded the stock from Buy to Hold and lowered the price target from $6 to $1.5.
Bolt Biotherapeutics shares dipped 34.4% to $0.8652 on Wednesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>AERWINS Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWIN#NASDAQ">AWIN</a>) shares surged 201% to $8.16.</li>
<li>Sintx Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) jumped 169% to $0.1449 after jumping over 41% on Tuesday. SINTX Technologies recently posted downbeat quarterly results.</li>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) jumped 87% to $0.5336 after jumping around 368% on Tuesday.</li>
<li>Edible Garden AG Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>) climbed 53.2% to $6.54 following first-quarter results.</li>
<li>iPower Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPW#NASDAQ">IPW</a>) gained 53% to $1.36 after the company reported better-than-expected third-quarter financial results.</li>
<li>Selina Hospitality PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNA#NASDAQ">SLNA</a>) jumped 51% to $0.0850.</li>
<li>Greenwave Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) shares gained 41% to $0.0627 after surging 7% on Tuesday.</li>
<li>Complete Solaria, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSLR#NASDAQ">CSLR</a>) gained 30.6% to $0.90. Complete Solaria signed a term sheet to eliminate Carlyle debt.</li>
<li>OptimizeRx Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) jumped 24% to $13.03 following upbeat quarterly results.</li>
<li>Blue Star Foods Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSFC#NASDAQ">BSFC</a>) rose 23% to $0.0686.</li>
<li>monday.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) jumped 21.5% to $220.93 after the company reported better-than-expected first-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Telos Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) gained 21.4% to $3.85.</li>
<li>BioCryst Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) rose 20% to $6.44.</li>
<li>Arcutis Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) rose 16.5% to $9.47 after the company reported better-than-expected first-quarter financial results.</li>
<li>Dolphin Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) rose 15.4% to $1.2999 after the company reported a year-over-year increase in first-quarter financial results.</li>
<li>Codere Online Luxembourg, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDRO#NASDAQ">CDRO</a>) jumped 14.3% to $7.98 following first-quarter results.</li>
<li>Nutriband Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) gained 13.5% to $4.34.</li>
<li>Riskified Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSKD#NYSE">RSKD</a>) jumped 12.8% to $6.05 following upbeat results.</li>
<li>Cabaletta Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) gained 12.8% to $12.66 following first-quarter results.</li>
<li>Jeffs&#8217; Brands Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) jumped 12% to $0.2530.</li>
<li>B&amp;G Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGS#NYSE">BGS</a>) rose 11.5% to $9.53.</li>
<li>Crown ElectroKinetics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRKN#NASDAQ">CRKN</a>) shares rose 11.2% to $0.0529.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) gained 8.1% to $0.0637 after adding around 12% on Tuesday.</li>
<li>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) rose 6% to $142.18 after Morgan Stanley maintained an Overweight rating on the stock and raised its price target from $128 to $152.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares fell 63.9% to $0.8199 after the company reported pricing of $2.25m public offering.</li>
<li>Yield10 Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) fell 49.4% to $2.66 after the company reported delisting from the Nasdaq.</li>
<li>Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) fell 45.8% to $0.4604 after the company announced pricing of $4.7 million public offering.</li>
<li>Pixelworks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXLW#NASDAQ">PXLW</a>) dipped 40.2% to $1.1186 after the company issued soft second-quarter guidance.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares fell 31.9% to $33.22 following a 60% surge on Tuesday.</li>
<li>Koss Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOSS#NASDAQ">KOSS</a>) dipped 31% to $4.24.</li>
<li>VirTra, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSI#NASDAQ">VTSI</a>) shares fell 30% to $11.49 after the company reported worse-than-expected first-quarter financial results.</li>
<li>MicroCloud Hologram Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) dipped 30.3% to $2.25.</li>
<li>SunPower Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) shares fell 29.6% to $3.0896. Wolfe Research analyst Steve Fleishman downgraded SunPower from Peer Perform to Underperform.</li>
<li>Intrusion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) shares declined 28.7% to $1.84 after the company reported downbeat first-quarter sales.</li>
<li>DLocal Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLO#NASDAQ">DLO</a>) fell 27.5% to $9.84 after the company reported weaker-than-expected first-quarter earnings and said there is a greater likelihood of coming in towards the lower end of its guidance range.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) fell 26.3% to $5.04 after jumping 32% on Tuesday.</li>
<li>Maxeon Solar Technologies, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAXN#NASDAQ">MAXN</a>) declined 25% to $2.7550.</li>
<li>The Oncology Institute, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) fell 24.4% to $0.6798 following weak quarterly results.</li>
<li>Cheetah Net Supply Chain Service Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) shares fell 23.2% to $4.92 after jumping 442% on Tuesday. The company priced a follow-on offering for gross proceeds of $8.19 million.</li>
<li>Nortech Systems Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSYS#NASDAQ">NSYS</a>) fell 21.1% to $11.97. Nortech Systems is expected to hold a conference call on Thursday, May 16, to discuss the company&#8217;s first quarter financial results.</li>
<li>Virgin Galactic Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NASDAQ">SPCE</a>) fell 16.5% to $1.06.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) declined 12.5% to $11.80.</li>
<li>Pulse Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) declined 12.1% to $6.74. Pulse Biosciences named Burke T. Barrett as President and Chief Executive Officer.</li>
<li>iRobot Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) fell 11.8% to $11.24.</li>
<li>BlackBerry Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) fell 10.2% to $3.11.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) fell 9.9% to $4.8000.</li>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) dipped 9.5% to $5.24. New reports indicate the company on Wednesday launched its first vehicle under its new Onvo brand.</li>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) fell 8.7% to $10.22.</li>
<li>Petróleo Brasileiro S.A. &#8211; Petrobras (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBR#NYSE">PBR</a>) shares fell 8.3% to $15.30. Brazil's President Luiz Inacio Lula da Silva fired Jean Paul Prates, the CEO of Petrobras, following a dispute over dividend.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/05/38844468/jim-cramer-this-industrial-company-is-absolutely-terrific-recommends-buying-modine-manufacturing">Jim Cramer: This Industrial Company Is &#8216;Absolutely Terrific&#8217;, Recommends Buying Modine Manufacturing</a>

Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock moved upwards by 136.2% to $0.13 during Wednesday's regular session. The company's market cap stands at $15.9 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) shares moved upwards by 45.55% to $6.06. The company's market cap stands at $81.9 million. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) shares rose 25.9% to $4.67. The company's market cap stands at $51.2 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares increased by 25.64% to $2.89. The company's market cap stands at $2.5 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) shares moved upwards by 22.8% to $12.87. The market value of their outstanding shares is at $234.0 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock increased by 20.57% to $1.0. The market value of their outstanding shares is at $50.7 million. As per the news, the Q1 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock decreased by 67.0% to $0.76 during Wednesday's regular session. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock fell 50.35% to $0.42. The company's market cap stands at $1.1 million. </li>
<li>Yield10 Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) stock decreased by 37.84% to $3.27. The company's market cap stands at $2.1 million. </li>
<li>Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) shares declined by 33.12% to $0.88. The company's market cap stands at $33.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) shares fell 18.91% to $0.73. The market value of their outstanding shares is at $54.2 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares declined by 18.27% to $1.61. The market value of their outstanding shares is at $3.6 million. The company's, Q1 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBLG

EYEN

TCON

TTOO

12 Health Care Stocks Moving In Wednesday's Intraday Session

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 150 points on Wednesday.
The Dow traded up 0.59% to 39,790.88 while the NASDAQ rose 0.93% to 16,665.13. The S&amp;P 500 also rose, gaining, 0.80% to 5,288.72.
Check This Out: <a href="https://www.benzinga.com/news/24/05/38840839/wall-streets-most-accurate-analysts-views-on-3-materials-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts&#8217; Views On 3 Materials Stocks Delivering High-Dividend Yields</a>
Leading and Lagging Sectors Utilities shares rose by 1.5% on Wednesday.
In trading on Wednesday, energy shares fell by 0.8%.
Top Headline
U.S. retail sales came in unchanged month-over-month in April compared to a revised 0.6% increase in March.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>OptimizeRx Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) shares shot up 25% to $13.12 following upbeat quarterly results.</li>
<li>Shares of Edible Garden AG Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>) got a boost, surging 31% to $5.60 following first-quarter results.</li>
<li>iPower Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPW#NASDAQ">IPW</a>) shares were also up, gaining 37% to $1.22 after the company reported better-than-expected third-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares dropped 63% to $0.83 after the company reported pricing of $2.25m public offering.</li>
<li>Shares of Pixelworks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXLW#NASDAQ">PXLW</a>) were down 40% to $1.1150 after the company issued soft second-quarter guidance.</li>
<li>Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) was down, falling 47% to $0.45 after the company announced pricing of $4.7 million public offering.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/24/05/38840642/dell-to-rally-over-13-here-are-10-top-analyst-forecasts-for-wednesday">Dell To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Wednesday</a>
Commodities In commodity news, oil traded down 0.7% to $77.47 while gold traded up 0.7% at $2,375.50.
Silver traded up 1.8% to $29.22 on Wednesday, while copper fell 0.1% to $4.8895.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.44%, Germany's DAX rose 0.68% and France's CAC 40 rose 0.01%. Spain's IBEX 35 Index rose 0.98%, while London's FTSE 100 rose 0.08%.
Industrial production in the Eurozone increased by 0.6% month-over-month in March compared to a revised 1% gain in the previous month. The Eurozone economy grew by 0.3% on quarter during the first three months, compared to a 0.1% decline in the prior quarter.
The annual inflation rate in France fell to 2.2% in April from 2.3% in March.
Asia Pacific Markets
Asian markets closed mostly lower on Wednesday, with Japan's Nikkei gaining 0.08%, China's Composite Index falling 0.82%, Hong Kong's Hang Seng Index falling 0.22% and India's S&amp;P BSE Sensex falling 0.22%.
Total passenger vehicle sales in India rose 1.2% year-over-year to 287,746 in April compared to an 8.9% rise in the prior month. The People&#8217;s Bank of China kept the interest rate unchanged at 2.50%.
Economics
<ul>
<li>Mortgage applications in the US rose 0.5% from the prior week in the period ending May 10.</li>
<li>U.S. consumer prices rose 0.3% month-over-month in April compared to 0.4% in the previous month, and also down from market expectations of 0.4%.</li>
<li>Annual inflation rate in the U.S. slowed to 3.4% in April from 3.5% a month ago.</li>
<li>U.S. retail sales came in unchanged month-over-month in April compared to a revised 0.6% increase in March.</li>
<li>The NY Empire State Manufacturing Index declined to -15.6 in May compared to -14.3 in the prior month, and versus market estimates of -10.0.</li>
<li>Total business inventories declined by 0.1% month-over-month in March compared to a revised 0.3% gain in February.</li>
<li>The NAHB/Wells Fargo Housing Market Index declined to 45.0 in May, recording the lowest level in four months.</li>
<li>Crude oil inventories in the U.S. declined by 2.508 million barrels in the week ending May 10, compared to a 1.362 million gain in the prior period.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/05/38839679/top-3-consumer-stocks-that-could-blast-off-this-month">Top 3 Consumer Stocks That Could Blast Off This Month</a>

WIIM

OptimizeRx shares are trading higher after the company reported better-than-expected Q1 financial results.

OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $14.6, with a high estimate of $17.00 and a low estimate of $13.00. This current average has increased by 12.31% from the previous average price target of $13.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1715778049_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of OptimizeRx by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Grossman</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>David Grossman</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$17.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to OptimizeRx. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of OptimizeRx compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of OptimizeRx's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into OptimizeRx's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/OPRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on OptimizeRx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About OptimizeRx</h2>
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
<h3>OptimizeRx: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, OptimizeRx showcased positive performance, achieving a revenue growth rate of 44.34% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: OptimizeRx's net margin excels beyond industry benchmarks, reaching -14.6%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): OptimizeRx's ROE stands out, surpassing industry averages. With an impressive ROE of -3.41%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): OptimizeRx's ROA stands out, surpassing industry averages. With an impressive ROA of -2.7%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: OptimizeRx's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.29.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For OptimizeRx

Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Buy and maintains $13 price target.

Stifel Maintains Buy on OptimizeRx, Maintains $13 Price Target

<h3>Gainers</h3>
<ul>
<li>Arcutis Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) stock moved upwards by 16.4% to $9.46 during Tuesday's after-market session. The company's market cap stands at $1.0 billion. As per the press release, Q1 earnings came out today. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) stock rose 13.02% to $2.95. The market value of their outstanding shares is at $141.9 million. As per the news, the Q1 earnings report came out today. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) stock increased by 7.55% to $11.25. The company's market cap stands at $204.5 million. As per the news, the Q1 earnings report came out today. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock moved upwards by 6.74% to $0.93. The market value of their outstanding shares is at $12.4 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares rose 6.08% to $2.44. The market value of their outstanding shares is at $2.1 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock rose 5.81% to $0.06. The market value of their outstanding shares is at $7.1 million. As per the press release, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) stock fell 15.9% to $1.11 during Tuesday's after-market session. The market value of their outstanding shares is at $42.3 million. </li>
<li>Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) stock declined by 12.86% to $2.17. The company's market cap stands at $6.4 million. The company's, Q1 earnings came out today. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) shares decreased by 12.0% to $2.71. The company's market cap stands at $44.0 million. As per the press release, Q1 earnings came out today. </li>
<li>Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) stock fell 7.66% to $66.0. The market value of their outstanding shares is at $3.2 billion. As per the press release, Q4 earnings came out today. </li>
<li>Akili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKLI#NASDAQ">AKLI</a>) shares decreased by 7.32% to $0.41. The market value of their outstanding shares is at $32.4 million. As per the news, the Q1 earnings report came out today. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares fell 5.77% to $1.47. The market value of their outstanding shares is at $50.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKLI

BCAB

IRIX

OCEA

VVOS

12 Health Care Stocks Moving In Tuesday's After-Market Session

OptimizeRx Reiterates FY24 Guidance With Revenue To Be At Least $100M (Est $101.313M), Adjusted EBITDA Of At Least $11M

In a report released today, Eric Martinuzzi from Lake Street reiterated a Buy rating on OptimizeRx (OPRX – Research Report), with a price target of...

Lake Street Remains a Buy on OptimizeRx (OPRX)

OptimizeRx Non-GAAP EPS of $0.02 beats by $0.09, revenue of $18.8M misses by $1.66M

OptimizeRx Corporation (OPRX) Q2 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
OptimizeRx (NASDAQ:<a href="https://investorplace.com/stock-quotes/oprx-stock-quote/">OPRX</a>) just reported results for the second quarter of 2024.<ul><li>OptimizeRx reported earnings per share of 2 cents. This was above the analyst estimate for EPS of -6 cents.</li><li>The company reported revenue of $18.81 million.</li><li>This was 6.92% worse than the analyst estimate for revenue of $20.21 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/oprx-stock-earnings-optimizerx-for-q2-of-2024/">OPRX Stock Earnings: OptimizeRx Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

OPRX Stock Earnings: OptimizeRx Beats EPS, Misses Revenue for Q2 2024

Analyst Constantine Davides from JMP Securities reiterated a Buy rating on OptimizeRx (OPRX – Research Report) and keeping the price target at $16....

OptimizeRx Maintains Buy Rating: Robust Sales Pipeline and Improved Operational Efficiency Signal Strong Future Growth

Roth MKM analyst Richard Baldry reiterated a Buy rating on OptimizeRx (OPRX – Research Report) today and set a price target of $20.00. The company'...

Roth MKM Sticks to Its Buy Rating for OptimizeRx (OPRX)

In a report released today, David Grossman from Stifel Nicolaus maintained a Buy rating on OptimizeRx (OPRX – Research Report), with a price target...

Stifel Nicolaus Reaffirms Their Buy Rating on OptimizeRx (OPRX)

Barclays analyst Stephanie Davis maintained a Hold rating on OptimizeRx (OPRX – Research Report) today and set a price target of $11.00. The compan...

Barclays Sticks to Its Hold Rating for OptimizeRx (OPRX)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on OptimizeRx (OPRX – Research Report) and Pulmonx (LUN...

Wall Street Analysts Are Bullish on Top Healthcare Picks

In a report released today, Constantine Davides from JMP Securities maintained a Buy rating on OptimizeRx (OPRX – Research Report), with a price ta...

OptimizeRx: A Strong Buy on Client Commitments and Growth Potential

LUNG

Press Releases

OptimizeRx Provides Business Update and Sets First Quarter 2024 Conference Call for May 14, 2024 at 4:30 p.m. ET

OptimizeRx to Participate in Upcoming Investor Conferences

OptimizeRx Reports First Quarter 2024 Financial Results

New White Paper Highlights How Closing the Health Information Gap Between Doctors and Patients Improves Life Science Marketing & Adds Value to Clinical Conversations

Health Care

General

OptimizeRx Demonstrates Measurable Script Lift for a Major Depressive Disorder Brand Targeting Physicians of Hard-to-Reach Patients

OptimizeRx Delivers AI-Guided Privacy-Compliant Platform for Pharmaceutical Brand Marketing Amid Evolving Consumer Privacy Legislation

OptimizeRx Sets Second Quarter 2024 Conference Call for August 8, 2024 at 4:30 p.m. ET

OptimizeRx Reports Second Quarter 2024 Financial Results

OptimizeRx Launches Novel Brand Eligibility Technology, Enabling Dynamic Direct to Consumer Marketing for Healthcare Audiences

OptimizeRx Continues to Expand its Strategic Relationship with a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment with Over $10M In-Year Total Value

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

OptimizeRx

OptimizeRx (OPRX) Forecast

OptimizeRx (NASDAQ:OPRX) Stock, Quote.Headers.trade-ideas